[68Ga]Ga-LNC1007 PET/CT在评估肾细胞癌中的应用: 与2-[18F]FDG/[68Ga]Ga-PSMA PET/CT的比较。
[68Ga]Ga‑LNC1007 PET/CT in the evaluation of renal cell carcinoma: comparison with 2-[18F]FDG/[68Ga]Ga-PSMA PET/CT.
发表日期：2023 Sep 20
作者：
Rong Lin, Chao Wang, Shaohao Chen, Tingting Lin, Hai Cai, Shaoming Chen, Yun Yang, Jiaying Zhang, Fuqi Xu, Jingjing Zhang, Xiaoyuan Chen, Jie Zang, Weibing Miao
来源：
Eur J Nucl Med Mol I
摘要：
为了比较[68Ga]Ga-LNC1007与2-[18F]FDG/[68Ga]Ga-PSMA PET/CT在检测肾细胞癌（RCC）方面的潜在效率，并探索从[68Ga]Ga-LNC1007 PET/CT中得出的参数来区分RCC的病理特征。本前瞻性研究纳入了经病理确认的25例RCC患者。在相应的PET/CT图像中，计算了病灶的最大标准摄取值（SUVmax）、平均SUV（SUVmean）、肿瘤总体积（GTV）和总病灶示踪剂（TL-tracer）。病理特征包括世界卫生组织/国际泌尿病理学学会（WHO/ISUP）分级和不良病理特征（肿瘤坏死、肉瘤或横纹肌瘤）。[68Ga]Ga-LNC1007 PET/CT显示出对原发病灶的检出率优于2-[18F]FDG和[68Ga]Ga-PSMA（LNC1007对FDG：13/17对4/17，P = 0.005；LNC1007对PSMA：9/11对6/11，P = 0.361）。[68Ga]Ga-LNC1007 PET/CT与2-[18F]FDG PET/CT相比显示出更高的SUVmax（6.6对3.7，P = 0.005）、SUVmean（4.1对2.3，P = 0.001）和TBR（2.6对1.7，P = 0.011），与[68Ga]Ga-PSMA PET/CT相比显示出更高的TBR（2.9对0.5，P = 0.003）、TBR-delay（2.8对0.3，P = 0.003）、GTV（84.1对42.9，P = 0.003）和TL-tracer（442.7对235.8，P = 0.008）。[68Ga]Ga-LNC1007 PET/CT得出的SUVmax和TBR可以有效区分WHO/ISUP分级（3-4对1-2）和不良病理特征（阳性对阴性）（SUVmax：AUC 0.81，P = 0.04；AUC 0.80，P = 0.033；TBR：AUC 0.84，P = 0.026；AUC 0.85，P = 0.014）。SUVmax与FAP表达、整合素αvβ3表达以及FAP和整合素αvβ3的总体表达呈正相关（r = 0.577，P = 0.006，r = 0.701，P < 0.001，r = 0.702，P < 0.001）。[68Ga]Ga-LNC1007是一种有前景的RCC显像示踪剂，可以有效识别RCC的侵袭性病理特征。© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
To compare the potential efficiency of [68Ga]Ga-LNC1007 with 2-[18F]FDG/[68Ga]Ga-PSMA PET/CT for detecting renal cell carcinoma (RCC) and to explore parameters derived from [68Ga]Ga-LNC1007 PET/CT for discriminating pathological characteristics in RCC.Twenty-five RCC patients confirmed by pathology were enrolled in this prospective study. The maximum standardized uptake value (SUVmax), mean SUV (SUVmean), gross tumor volume (GTV) and total lesion-tracer (TL-tracer) of lesions were calculated from the corresponding PET/CT images. Pathological characteristics included World Health Organization/International Society of Urological Pathology (WHO/ISUP) grade and adverse pathological features (tumor necrosis or sarcomatoid or rhabdoid feature).[68Ga]Ga-LNC1007 PET/CT showed a higher detection rate for primary lesions than 2-[18F]FDG and [68Ga]Ga-PSMA (LNC1007 vs. FDG: 13/17 vs. 4/17, P = 0.005; LNC1007 vs. PSMA: 9/11 vs. 6/11, P = 0.361). [68Ga]Ga-LNC1007 PET/CT showed higher SUVmax (6.6 vs. 3.7, P = 0.005), SUVmean (4.1 vs. 2.3, P = 0.001) and TBR (2.6 vs. 1.7, P = 0.011) compared with 2-[18F]FDG PET/CT, and it also showed higher TBR (2.9 vs. 0.5, P = 0.003), TBR-delay (2.8 vs. 0.3, P = 0.003), GTV (84.1 vs. 42.9, P = 0.003) and TL-tracer (442.7 vs. 235.8, P = 0.008) compared with [68Ga]Ga-PSMA PET/CT. SUVmax and TBR derived from [68Ga]Ga-LNC1007 PET/CT could effectively differentiate WHO/ISUP grade (3-4 vs. 1-2) and adverse pathological features (positive vs. negative) (SUVmax: AUC 0.81, P = 0.04; AUC 0.80, P = 0.033; TBR: AUC 0.84, P = 0.026; AUC 0.85, P = 0.014). The SUVmax was positively correlated with the FAP expression, integrin αvβ3 expression and the total expression of FAP and integrin αvβ3 (r = 0.577, P = 0.006, r = 0.701, P < 0.001, and r = 0.702, P < 0.001, respectively).[68Ga]Ga-LNC1007 is a promising tracer for RCC imaging and can effectively identify aggressive pathological characteristics of RCC.© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.